Drugs / F182112
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04984434 | Jul 2021 → Jul 2023 | belinostat toxicity or dose selection | Shandong New Time Pharmaceutical Co., LTD | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07312188 | Jul 2025 → May 2028 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07579234 | Jan 2026 → Jan 2029 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F182112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04984434 ↗ |
| Route | Intravenous | “when infused intravenously (IV)” NCT04984434 ↗ |